Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study

Lung Cancer

Volumn 79, Issue 2, 2013, Pages 143-150

  Sun, Y ^a   Wu, Y L ^b   Zhou, C C ^c   Zhang, L ^d,e   Liu, X Y ^e   Yu, S Y ^f   Jiang, G L ^g   Li, K ^h   Qin, S K ⁱ   Ma, S L ^j   Han, L ^k   Quinlivan, M ^k   Orlando, M ^l   Zhang, X Q ^m  

^a CANCER HOSPITAL   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^h TIANJIN MEDICAL UNIVERSITY   (China)

ⁱ PLA Cancer Center   (China)

^j ZHEJIANG CANCER HOSPITAL   (China)

^k ELI LILLY AND COMPANY   (United States)

^l Eli Lilly Interamérica Inc Suc Argentina   (Argentina)

^m Eli Lilly Asia   (China)

more..

Author keywords

Carcinoma; Clinical trial; Docetaxel; Non small cell lung; Pemetrexed

Indexed keywords

DOCETAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFESTATION; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THORAX DISEASE; THROMBOCYTE COUNT; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; TAXOIDS; TREATMENT OUTCOME;

EID: 84872123438     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.10.015     Document Type: Article

References (36)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Zhao P., Dai M., Chen W., Li N. Cancer trends in China. Jpn J Clin Oncol 2010, 40:281-285.
3. Sorenson S., Glimelius B., Nygren P. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol 2001, 40:327-339.
4. Fathi A.T., Brahmer J.R. Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2008, 20:210-216.
5. Curtin N.J., Hughes A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol 2001, 2:298-306.
6. Schultz R.M., Patel V.F., Worzalla J.F., Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999, 19:437-443.
7. Shih C., Habeck L.L., Mendelsohn L.G., Chen V.J., Schultz R.M. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998, 38:135-152.
8. Baldwin C.M., Perry C.M. Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer. Drugs 2009, 69:2279-2302.
9. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
10. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
11. Marsh S., Collie-Duguid E.S., Li T., Liu X., McLeod H.L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999, 58:310-312.
12. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
13. Sigmond J., Backus H.H., Wouters D., Temmink O.H., Jansen G., Peters G.J. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003, 66:431-438.
14. Wu M., Zhao J., Song S.W., Zhuo M., Wang X., Bai H., et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2010, 67:343-347.
15. Tanaka F., Wada H., Fukui Y., Fukushima M. Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol 2011, 22:1791-1797.
16. Esteban E., Casillas M., Cassinello A. Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev 2009, 35:364-373.
17. Selvaggi G., Scagliotti G.V. Histologic subtype in NSCLC: does it matter?. Oncology (Williston Park) 2009, 23:1133-1140.
18. Hollen P.J., Gralla R.J., Kris M.G., Cox C., Belani C.P., Grunberg S.M., et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994, 73:2087-2098.
19. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
20. Cox D. Regression models and life tables. J Royal Stat Soc Series B (Methodological) 1972, 34:187-220.
21. Perng R.P., Shih J.F., Chen Y.M., Chou K.C., Lee Y.C., Tsai C.M. A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer. Jpn J Clin Oncol 2000, 30:429-434.
22. Ou S.H., Ziogas A., Zell J.A. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009, 4:1083-1093.
23. Hirsch F.R., Bunn P.A. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009, 10:432-433.
24. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
25. Lee H.Y., Ahn M.J., Park Y.H., Ahn J.S., Kim B.S., Kim H.K., et al. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. Lung Cancer 2009, 66:338-343.
26. Scagliotti G.V., Parikh P., von P.J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
27. Wu Y.L., Zhong W.Z., Li L.Y., Zhang X.T., Zhang L., Zhou C.C., et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007, 2:430-439.
28. Mok T., Wu Y.L., Au J.S., Zhou C., Zhang L., Perng R.P., et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:1609-1615.
29. Kubota K., Niho S., Enatsu S., Nambu Y., Nishiwaki Y., Saijo N., et al. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol 2009, 4:1530-1536.
30. Peterson P., Park K., Fossella F., Gatzemeier U., John W., Scagliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007, 2:S851.
31. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14:253-263.
32. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
33. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 2000, 18:2354-2362.
34. Cullen M.H., Zatloukal P., Sörenson S., Novello S., Fischer J.R., Joy A.A., et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008, 19:939-945.
35. Ohe Y., Ichinose Y., Nakagawa K., Tamura T., Kubota K., Yamamoto N., et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4206-4212.
36. Russo F., Bearz A., Pampaloni G. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 2008, 8:216-222.